Stability of solvent/detergent-treated plasma and single-donor fresh-frozen plasma during 48 h after thawing

Transfusion and Apheresis Science

Volumn 33, Issue 3, 2005, Pages 257-267

  Heger, Andrea ^a   Römisch, Jürgen ^a   Svae, Tor Einar ^a  

^a Octapharma Pharmazeutika Produktions GmbH   (Austria)

Author keywords

FFP; Octaplas; SD plasma; Stability after thawing

Indexed keywords

ALPHA 2 ANTIPLASMIN; BLOOD CLOTTING FACTOR; BLOOD CLOTTING FACTOR 11; BLOOD CLOTTING FACTOR 5; BLOOD CLOTTING FACTOR 7; BLOOD CLOTTING FACTOR 7A; BLOOD CLOTTING FACTOR 8; BLOOD CLOTTING FACTOR 9; FRESH FROZEN PLASMA; OCTAPLAS; PLASMA SUBSTITUTE; PLASMIN INHIBITOR; PROTEIN C; PROTEIN S; PROTEINASE INHIBITOR; UNCLASSIFIED DRUG; VON WILLEBRAND FACTOR;

ARTICLE; BLOOD CLOTTING; BLOOD STORAGE; COMPARATIVE STUDY; TEMPERATURE; THAWING;

BLOOD COAGULATION TESTS; CRYOPRESERVATION; DETERGENTS; FACTOR VIIIA; HUMANS; PLASMA; SOLVENTS; TIME FACTORS; VON WILLEBRAND FACTOR;

EID: 27744459108     PISSN: 14730502     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.transci.2005.07.005     Document Type: Article

References (38)

1. H. Haubelt, M. Blome, A.H. Kieslling, F. Isgro, J. Bach, and W. Saggau Effects of solvent/detergent-treated plasma and fresh-frozen plasma on haemostasis and fibrinolysis in complex coagulopathy following open-heart surgery Vox Sang 82 2002 9 14
2. M.M. Mueller, B. Bomke, and E. Seifried Fresh frozen plasma in patients with disseminated intravascular coagulation or in patients with liver diseases Thromb Res 107 2002 9 17
3. J.W. Freeman, L.M. Williamson, C. Llewelyn, N. Fisher, J.P. Allain, and M. Bellamy A randomized trial of solvent/detergent and standard fresh frozen plasma in the treatment of the coagulopathy seen during orthotopic liver transplantation Vox Sang 74 1998 225 229
4. P. Hellstern, E. Larbig, G.A. Walz, W. Thürogen, and K. Oberfrank Prospective study on efficacy and tolerability of solvent/detergent-treated plasma in intensive care unit patients Infusionsther Transfusionsmed 20 1993 16 18
5. J.E. Pimanda, C.N. Chesterman, and P.J. Hogg A perspective on the measurement of ADAMTS13 in thrombotic thrombocytopenic purpura Eur J Haematol 70 4 2003 257 262
6. D. Barz, U. Budde, and P. Hellstern Therapeutic plasma exchange and plasma infusion in thrombotic microvascular syndromes Thromb Res 107 2002 23 27
7. K. Kentouche, U. Budde, M. Furlan, R. Schneppenheim, and F. Zintl Remission of thrombotic thrombocytopenic purpura in a patient with compound heterozygous deficiency of von Willebrand factor-cleaving protease by infusion of solvent/detergent plasma Acta Paediatr 91 2002 1056 1059
8. J. Barbot, E. Costa, M. Guerra, M. Barreirinho, P. Isvarlal, and R. Robles Ten years of prophylactic treatment with fresh-frozen plasma in a child with chronic relapsing thrombotic thrombocytopenic purpura as a result of a congenital deficiency of von Willebrand factor-cleaving protease Br J Haematol 113 2001 649 651
9. W. Muntean Fresh frozen plasma in the pediatric age group and in congenital coagulation factor deficiency Thromb Res 107 2002 29 32
10. M.S. Horowitz, and J.C. Pehta SD plasma in TTP and coagulation factor deficiencies for which no concentrates are available Vox Sang 74 1998 231 235
11. B. Horowitz, A. Lazo, H. Grossberg, G. Page, A. Lippin, and G. Swan Virus inactivation by solvent/detergent treatment and the manufacture of SD-plasma Vox Sang 74 1 1998 203 206
12. D. Josic, P. Schulz, L. Biesert, L. Hoffer, H. Schwinn, and M. Kordis-Krapez Issues in the development of medical products based on human plasma J Chromatogr B 694 1997 253 269
13. B. Horowitz, R. Bonomo, A.M. Prince, S.N. Chin, B. Brotman, and R.W. Shulman Solvent/detergent-treated plasma: a virus-inactivated substitute for fresh frozen plasma Blood 79 3 1992 826 831
14. B.G. Solheim, H. Rollag, J.L. Svennevig, O. Arafa, E. Fosse, and U. Bergerud Viral safety of solvent/detergent-treated plasma Transfusion 40 2000 84 90
15. D. Pamphilon Viral inactivation of fresh frozen plasma Br J Haematol 109 4 2000 680 693
16. L. Biesert, and H. Suhartono Solvent/detergent treatment of human plasma - a very robust method for virus inactivation. Validated virus safety of Octaplas Vox Sang 74 1 1998 207 212
17. F. Morfeld, R. Schütz, Dj. Josic, and H. Schwinn Manufacturing and down scaling process for a virus-inactivated pooled human plasma Pharm Ind 58 1996 433 435
18. J.U. Wiedling, P. Hellstern, and M. Köhler Inactivation of viruses in fresh-frozen plasma Ann Hematol 67 1993 259 266
19. O. Flesland, J. Seghatchian, and B.G. Solheim The Norwegian plasma fractionation project-a 12 year clinical and economic success story Transfusion Apher Sci 28 2003 93 100
20. P. Hellstern, and H. Haubelt Manufacture and composition of fresh frozen plasma and virus-inactivated therapeutic plasma preparations: correlation between composition and therapeutic efficacy Thromb Res 107 2002 3 8
21. P. Hellstern, W. Muntean, W. Schramm, E. Seifried, and B.G. Solheim Practical guidelines for the clinical use of plasma Thromb Res 107 2002 53 57
22. R.G. Lerner, J. Nelson, E. Sorcia, K. Grima, R.R. Kancherla, and C.M. Zarou-Naimo Evaluation of solvent/detergent-treated plasma in patients with a prolonged prothrombin time Vox Sang 79 2000 161 167
23. G.F. Riedler, A.R. Haycox, A.K. Duggan, and H.A. Dakin Cost-effectiveness of solvent/detergent-treated fresh-frozen plasma Vox Sang 85 2003 88 95
24. C.C. Silliman, L.K. Boshkov, Z. Mohdizadohkashi, D.J. Elzi, W.O. Dickey, and L. Podlosky Transfusion-related acute lung injury: epidemiology and a prospective analysis of etiologic factors Blood 101 2003 454 462
25. The Serious Hazards of Transfusion Steering Group. Serious Hazards of Transfusion: (SHOT)-Summary of Annual Report 2001-2002. Manchester; 2003.
26. British Committee for Standards in Haematology Guidelines for the use of fresh frozen plasma Transfus Med 2 1992 57 63
27. British Committee for Standards in Haematology Guidelines for the use of fresh-frozen plasma, cryoprecipitate and cryosupernatant Br J Haematol 126 2004 11 28
28. Council of Europe Recommendation No. R (95) 15 on the Preparation, use and quality assurance in blood components 1995 Council of Europe Press Strasbourg
29. Council of Europe Recommendation No. R (86) 6 on Guidelines for the preparation, quality control and use of fresh frozen plasma (FFP) 1986 Council of Europe Press Strasbourg
30. United Kingdom Blood Transfusion Services/National Institute for Biological Standards and Control (2002) Guidelines for the blood transfusion services in the United Kingdom, 6th ed. TSO. W W W document. URL: http://www.thestationeryoffice.com.nbs/rdbk2001/guidelines.htm and http://www.transfusionguidelines.org.uk.
31. US Food and Drug Administration. Guidance for industry. An acceptable circular of information for the use of human blood and blood components; 12 September 2003.
32. H. Beeck, and P. Hellstern In vitro characterization of solvent/detergent-treated human plasma and of quarantine fresh frozen plasma Vox Sang 74 1 1998 219 223
33. G. Lutze Blood clotting factors: determination of activity and concentration of blood clotting factors in conventional and virus inactivated coagulative plasma Krankenhauspharmazie 9 1994 517
34. P. Hellstern, H. Sachse, H. Schwinn, and K. Oberfrank Manufacture and in vitro characterization of a solvent/detergent-treated human plasma Vox Sang 63 1992 178 185
35. S. Doyle, P. O'Brien, K. Murphy, C. Fleming, and J. O'Donnell Coagulation factor content of solvent/detergent plasma compared with fresh frozen plasma Blood Coagul Fibrinol 14 2003 282 287
36. K.H. Beeck, Y. Mortelmans, V. Kretschmer, W. Höltermann, and P. Lukasewitz Comparison of solvent/detergent-inactivated plasma and fresh frozen plasma under routine clinical conditions Infus Ther Transfus Med 27 2000 144 148
37. A.D. Sharma, G. Sreeram, T. Erb, and H.P. Grocott Solvent-detergent- treated fresh frozen plasma: a superior alternative to standard fresh frozen plasma J Cardiothorac Vasc Anesth 14 2000 712 717
38. C. Buchta, M. Felfernig, P. Höcker, M. Macher, G.F. Körmöczi, and P. Quehenberger Stability of coagulation factors in thawed, solvent/detergent-treated plasma during storage at 4°C for 6 days Vox Sangs 87 2004 182 186